361
Participants
Start Date
September 1, 2022
Primary Completion Date
February 18, 2032
Study Completion Date
February 18, 2032
mRNA-4359
Intramuscular Injection
Pembrolizumab
Intravenous infusion
Ipilimumab
Intravenous infusion
Nivolumab
Intravenous infusion
RECRUITING
Melanoma Institute Australia, Wollstonecraft
RECRUITING
Southside Cancer Center, Miranda
RECRUITING
Austin Hospital, Melbourne
RECRUITING
One Clinical Research, Nedlands
RECRUITING
George Washington University, Washington D.C.
COMPLETED
Carolina BioOncology Institute, Huntersville
RECRUITING
NEXT Oncology Madrid, Madrid
RECRUITING
Orlando Health UF Health Cancer Center, Orlando
RECRUITING
Sara Cannon Research Institute Tennessee, Nashville
RECRUITING
Henry Ford Hospital, Detroit
RECRUITING
The University of Chicago Medicine, Chicago
RECRUITING
Washington University, St Louis
RECRUITING
University of Colorado Cancer Center, Aurora
RECRUITING
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
RECRUITING
Oregon Health Sciences University, Portland
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Dana Farber Cancer Institute, Boston
RECRUITING
John Theurer Cancer Center, Hackensack
RECRUITING
NEXT Oncology Barcelona, Barcelona
RECRUITING
Beatson West of Scotland Cancer Centre, Glasgow
RECRUITING
Queen Elizabeth Hospital Birmingham, Birmingham
RECRUITING
University College London Hospitals NHS Foundation Trust, London
RECRUITING
Guy's and St. Thomas' NHS Foundation Trust, London
RECRUITING
Imperial College London, London
RECRUITING
Churchill Hospital, Oxford
RECRUITING
University Hospital Southampton NHS Foundation Trust, Southampton
ModernaTX, Inc.
INDUSTRY